Dermatology · Far Rockaway, NY
NPI
1891119285
Since 2014
Specialty
Dermatology
Code 207N00000X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
327 Beach 19th St
Far Rockaway, NY, 11691
Phone (718) 869-7108
Groups this clinician bills Medicare through
Medicare paid, 2024
$239K
4,084 services
Medicare patients, 2024
1,139
Average age 74
Drug cost, 2024
$523K
1,498 prescriptions
Company payments, 2025
$3,010
From 19 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Vanita Srivastava was code 99213 (office e&m - established), 1,274 times for 835 patients. In total Vanita Srivastava billed 4,084 services in 31 codes, and Medicare paid $239K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2017-04-17.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Office | 1,274 | 835 | $74.47 | $95K |
| 17003 Destruction Skin Lesion | Office | 743 | 167 | $5.99 | $4,449 |
| 11102 Skin Biopsy | Office | 467 | 392 | $78.91 | $37K |
| 17000 Destruction Skin Lesion | Office | 414 | 292 | $46.23 | $19K |
| 99203 Office E&M - New | Office | 267 | 267 | $82.98 | $22K |
| 17110 Destruction Skin Lesion | Office | 263 | 225 | $95.11 | $25K |
| 11103 Skin Biopsy | Office | 172 | 110 | $45.93 | $7,900 |
| 99214 Office E&M - Established | Office | 74 | 62 | $110.32 | $8,164 |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 44 | 21 | $0.73 | $32.17 |
| 99204 Office E&M - New | Office | 31 | 31 | $129.15 | $4,004 |
| 11900 Skin | Office | 30 | 20 | $46.82 | $1,405 |
| 10040 Removal or Shaving of Skin Growth | Office | 27 | 27 | $100.65 | $2,718 |
| 17262 Destruction Skin Lesion | Office | 26 | 20 | $146.19 | $3,801 |
| 10060 Skin | Office | 14 | 14 | $101.19 | $1,417 |
By year: 2022 $190K for 3,277 services; 2023 $217K for 3,603 services; 2024 $239K for 4,084 services.
Medicare prescription drug claims, 2024
In 2024, the drug Vanita Srivastava prescribed most often to Medicare patients was Clobetasol Propionate, with 146 prescriptions and refills. In total Vanita Srivastava wrote 1,498 Medicare prescriptions that cost $523K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Clobetasol Propionate Generic | 146 | 173 | 87 | $6,069 |
| Ketoconazole Generic | 143 | 173 | 70 | $2,302 |
| Doxycycline Hyclate Generic | 128 | 297 | 60 | $4,202 |
| Triamcinolone Acetonide Generic | 109 | 115 | 96 | $1,249 |
| Fluorouracil Generic | 103 | 109 | 91 | $6,223 |
| Metronidazole Generic | 77 | 87 | 36 | $2,832 |
| Hydrocortisone Generic | 62 | 62 | 52 | $260 |
| Finasteride Generic | 53 | 159 | 23 | $345 |
| Clindamycin Phosphate Generic | 51 | 62 | 27 | $3,179 |
| Tacrolimus Generic | 49 | 80 | 31 | $6,252 |
| Tretinoin Generic | 47 | 53 | 26 | $2,324 |
| Mupirocin Generic | 44 | 46 | 38 | $467 |
| Ammonium Lactate Generic | 38 | 47 | 11 | $744 |
| Doxycycline Ir-Dr Doxycycline Monohydrate | 35 | 77 | 17 | $38K |
| Mometasone Furoate Generic | 34 | 34 | 29 | $628 |
Brand drugs: 256 claims; generic drugs: 1,242 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Vanita Srivastava $3,010 ($3,010 in general payments such as food, travel and fees) from 19 companies. The largest payer was Janssen Biotech, Inc. with $401.
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. JNJ | 15 | $401 |
| Novartis Pharmaceuticals Corporation NVS | 24 | $325 |
| Sun Pharmaceutical Industries Inc. SUNPHARMA.NS | 16 | $309 |
| UCB, Inc. UCB.BR | 18 | $298 |
| LEO Pharma Inc. | 12 | $224 |
| Lilly USA, LLC LLY | 12 | $220 |
| Regeneron Healthcare Solutions, Inc. REGN | 9 | $209 |
| Abbvie Inc. ABBV | 8 | $192 |
| Incyte Corporation INCY | 12 | $184 |
| Galderma Laboratories, L.P. GALD.SW | 10 | $179 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.